Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback